Table 1.
Patient characteristics
| Characteristics | Data, n (%) |
| Gender | |
| Female | 36 (48) |
| Male | 39 (52) |
| Age (yr) | |
| median (range) | 52 (29-74) |
| ≤ 60 | 58 (77.3) |
| > 60 | 17 (22.7) |
| Pre-CEA (ng/mL) | |
| ≤ 5 | 36 (63.2) |
| > 5 | 21 (36.8) |
| Pre-Hb (g/L) | |
| ≤ 120 | 26 (34.7) |
| > 120 | 49 (65.3) |
| Distance to verge (cm) | |
| ≤ 5 | 46 (61.3) |
| > 5 | 29 (38.7) |
| T stage | |
| T1 + T2 | 13 (17.3) |
| T3 + T4 | 63 (82.6) |
| Lymph node metastasis | |
| Negative | 22 (29.3) |
| Positive | 53 (70.6) |
| Venous invasion | |
| Negative | 68 (90.7) |
| Positive | 7 (9.3) |
| Tumor differentiation | |
| Poorly differentiated | 20 (26.7) |
| Moderately-well differentiated | 55 (73.3) |
| Chemotherapy | |
| No | 9 (12) |
| Yes | 66 (88) |
| TUBB3 expression | |
| Low-expression | 39 (52) |
| High-expression | 36 (48) |
| VEGFR1 expression | |
| Low-expression | 53 (70.7) |
| High-expression | 22 (29.3) |
| TUBB3 and VEGFR1 | |
| Both low expression | 32 (42.6) |
| Others | 43 (57.3) |
Pre-CEA: Preoperative carcino-embryonic antigen; Pre-Hb: Preoperative hemoglobin.